Skip to main content
P

Polaris Group — Investor Relations & Filings

Ticker · 6550 TW Manufacturing
Open in API
Filings indexed 46 across all filing types
Latest filing 2026-04-24 Regulatory Filings
Country TW Taiwan
Listing TW 6550

About Polaris Group

https://www.polarispharma.com

Polaris Group is a biotechnology company dedicated to the development of novel anti-cancer therapies and the provision of Contract Development and Manufacturing Organization (CDMO) services. The company’s core research focuses on ADI-PEG 20 (pegargiminase), a biological agent that utilizes metabolic therapy to target arginine-dependent cancers. This candidate is currently in late-stage clinical development for multiple indications, including mesothelioma, soft tissue sarcoma, and hepatocellular carcinoma. Polaris Group maintains a vertically integrated business model, encompassing drug design, clinical trial management, and internal manufacturing capabilities. It operates cGMP-compliant facilities and has expanded its CDMO portfolio to include complex injectables and synthetic peptides. The company aims to deliver innovative treatment options by leveraging its proprietary technology and global clinical partnerships.

Recent filings

Filing Released Lang Actions
115年年報及股東會資料 — 2025_6550_20260515FE7.pdf
Regulatory Filings
2026-04-24 Chinese
115年年報及股東會資料 — 2025_6550_20260515F18.pdf
Annual Report Classification · 100% confidence The document is titled '年報' (Annual Report) for Polaris Group for the year 114 (2025). It contains comprehensive sections including a letter to shareholders, company profile, corporate governance reports, financial performance analysis, and detailed operational information. It is a full-length annual report, not an announcement or a summary, and it contains substantive financial data and management analysis. FY 2025
2026-04-24 Chinese
114年年報及股東會資料 — 2025_6550_20251226FE3.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is the official minutes of the Second Extraordinary Shareholders’ Meeting, including detailed proposal discussions and, crucially, the formal voting results (votes in favor, against, abstained). This aligns with the definition of Declaration of Voting Results & Voting Rights Announcements, which covers official results from shareholder votes at any general meeting (AGM or EGM). Therefore, the correct classification is DVA.
2026-04-24 English
114年年報及股東會資料 — 2024_6550_20250521F11.pdf
Regulatory Filings
2026-04-24 Chinese
115年年報及股東會資料 — 2026_6550_20260515FE2.pdf
AGM Information Classification · 94% confidence The document is the complete Handbook for the 2026 Annual General Meeting of Shareholders, containing agenda, report matters, ratification and discussion proposals, election matters, appendices (business report, audit committee review, auditors’ report, remuneration details, etc.). It is clearly the materials distributed for an AGM, matching the AGM Information category rather than a separate annual report or earnings release.
2026-04-14 English
115年年報及股東會資料 — 2026_6550_20260515F02.pdf
AGM Information Classification · 95% confidence The document is the official “議事手冊” (meeting handbook) for the 115th Annual General Meeting of Polaris Group, containing the AGM agenda, proposals (reports, approvals, discussions, elections), and attachments (2025 business report, audit committee report, auditor’s report and financial statements, director remuneration details, etc.). It serves as the materials provided to shareholders at the Annual General Meeting rather than the standalone annual report itself. This matches the definition of AGM Information (AGM-R).
2026-04-14 English

Browse filings by year

1 year

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.